Regimmune To Start Phase I Study For Novel Immune Drug In The U.S.
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based drug discovery firm Regimmune has started a Phase I study for immunosuppressant RGI-2001 in the U.S